Eckert & Ziegler Strahlen- und Medizintechnik AG

Regulatory Filings • Dec 3, 2009

News Details

Ad-hoc | 3 December 2009 10:46

Eckert & Ziegler: Re-Enter the U.S Market with Therapeutic Products

Eckert & Ziegler Strahlen- und Medizintechnik AG / Alliance

03.12.2009

Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted by
DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.

---

Berlin, December 3rd, 2009. -- The Radiation Therapy Division of Eckert &
Ziegler (ISIN DE0005659700) is preparing its re-entry into the U.S. market.
As the Belgian portfolio company IBt Bebig reported last night, it has
entered into a strategic alliance with Core Oncology Inc. of Santa Barbara,
California, USA. The agreement calls for covering initially the cross
marketing of products of both companies and the definition of mutual R&D
programs. As part of the agreement, IBt Bebig made a two million USD
investment in Core Oncology. The investment has taken the form of a
subordinated loan maturing before the end of 2010. Both groups are
investigating the possibilities to collaborate further together. The board
of Eckert & Ziegler expects already in 2010 stimuli from the close
collaboration for further growth in revenues and profits of the Therapy
segment. It is also expected that the Radiation Therapy Division, like the
whole group, can at least double its revenues within the next five years
while maintaining the profitability.

---

Information and Explaination of the Issuer to this News:

For further details see also the publication at www.ibt-bebig.eu

Eckert & Ziegler AG, Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, D-13125 Berlin
Tel.: +49 (0) 30 / 94 10 84-138, Fax -112
E-Mail: karolin.riehle@ezag.de, www.ezag.com

03.12.2009 Financial News distributed by DGAP. Media archive at www.dgap-medientreff.de and www.dgap.de

---

Language: English
Company: Eckert & Ziegler Strahlen- und Medizintechnik AG
Robert-Rössle-Str.10
13125 Berlin
Deutschland
Phone: 49 30 941084-138
Fax: 49 30 941084-112
E-mail: karolin.riehle@ezag.de
Internet: www.ezag.de
ISIN: DE0005659700, DE000A0L1L69
WKN: 565970, A0L1L6
Listed: Regulierter Markt in Frankfurt (Prime Standard), Stuttgart;
Freiverkehr in Berlin, München, Düsseldorf, Hamburg

End of News DGAP News-Service

---